At the time of writing, NewAmsterdam Pharma Company NV [NAMS] stock is trading at $26.69, down -0.15%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NAMS shares have gain 10.33% over the last week, with a monthly amount glided 9.75%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NewAmsterdam Pharma Company NV [NASDAQ: NAMS] stock has seen the most recent analyst activity on August 25, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $45. Previously, Goldman started tracking the stock with Neutral rating on July 17, 2025, and set its price target to $27. On June 17, 2025, Citigroup initiated with a Buy rating and assigned a price target of $42 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $44 on June 10, 2025. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $42 as its price target on June 04, 2025. H.C. Wainwright started tracking with a Buy rating for this stock on December 30, 2024, and assigned it a price target of $48. In a note dated May 15, 2024, TD Cowen initiated a Buy rating.
For the past year, the stock price of NewAmsterdam Pharma Company NV fluctuated between $14.06 and $27.35. Currently, Wall Street analysts expect the stock to reach $45 within the next 12 months. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $26.69 at the most recent close of the market. An investor can expect a potential return of 68.6% based on the average NAMS price forecast.
Analyzing the NAMS fundamentals
According to NewAmsterdam Pharma Company NV [NASDAQ:NAMS], the company’s sales were 64.01M for trailing twelve months, which represents an 740.06% jump. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -2.7%, Pretax Profit Margin comes in at -2.59%, and Net Profit Margin reading is -2.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.25 and Total Capital is -0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that NewAmsterdam Pharma Company NV [NASDAQ:NAMS] has a current ratio of 21.08. In addition, the Quick Ratio stands at 21.08 and the Cash Ratio stands at 15.44. Considering the valuation of this stock, the price to sales ratio is 46.96, the price to book ratio is 3.86.
Transactions by insiders
Recent insider trading involved Topper James N, Director, that happened on Sep 15 ’25 when 660.0 shares were purchased. Chief Accounting Officer, Kooij Louise Frederika completed a deal on Sep 09 ’25 to sell 0.15 million shares. Meanwhile, Director Topper James N bought 1260.0 shares on Sep 08 ’25.
